Remix Therapeutics is set to go public via a reverse merger with Passage Bio, a gene therapy company co-founded by Jim Wilson. Under the agreement, the combined entity is expected to close in the fourth quarter and will trade under the Remix name with the ticker symbol RMTX. Remix investors are expected to own about 93% of the new company, while Passage shareholders receive about 7% plus a contingent value right potentially linked to licensed pediatric gene therapy assets. The companies also secured commitments for a $100 million private financing round intended to fund operations into 2028. The transaction reflects a survival-and-scale strategy for Passage Bio after regulatory setbacks and Gene therapy market pullback, while Remix’s RNA-targeting approach and earlier partnerships with large pharma support a new go-forward platform.